← Back to Search

Glutamate Receptor Antagonist

perampanel for Essential Tremor

Phase 2
Waitlist Available
Led By Charles A Handforth, M.D.
Research Sponsored by VA Greater Los Angeles Healthcare System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40 weeks
Awards & highlights

Summary

Obtain information on whether the medication Perampanel reduces tremor in people with essential tremor and is well-tolerated.

Eligible Conditions
  • Essential Tremor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 40 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety. Laboratory testing; screen visit testing
Safety. vitals;
Safety; laboratory testing
+5 more
Secondary outcome measures
QOLIE changes
Subjective assessment of global life changes
Treatment effects on Daily Living (The QUEST scale to assess quality of life)

Side effects data

From 2021 Phase 4 trial • 54 Patients • NCT03288129
28%
Dizziness
17%
Fatigue
15%
Somnolence
11%
Vomiting
9%
Nasopharyngitis
9%
Irritability
9%
Headache
7%
Nausea
7%
Ear infection
6%
Upper respiratory tract infection
6%
Balance disorder
6%
Memory impairment
6%
Aggression
6%
Depression
6%
Oropharyngeal pain
2%
Mental status changes
2%
Sudden unexplained death in epilepsy
2%
Transient ischaemic attack
2%
Suicidal ideation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Perampanel 12 mg

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: perampanelExperimental Treatment1 Intervention
Perampanel administration
Group II: placeboPlacebo Group1 Intervention
Placebo administered to subjects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perampanel
FDA approved

Find a Location

Who is running the clinical trial?

VA Greater Los Angeles Healthcare SystemLead Sponsor
51 Previous Clinical Trials
8,551 Total Patients Enrolled
2 Trials studying Essential Tremor
41 Patients Enrolled for Essential Tremor
Charles A Handforth, M.D.Principal InvestigatorVHAGLAHS
~2 spots leftby Jul 2025